Serotonin2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients.
Serotonin2 (5-HT2) receptor binding was studied, using 3H-spiperone as the ligand, in post-mortem brain specimens obtained from schizophrenic patients (N = 11) and non-psychiatric controls (N = 11). The maximum number of binding sites (Bmax) was significantly decreased in schizophrenic patients as compared to normal controls. This difference did not appear to be due to neuroleptic treatment. No difference in Kd (an inverse measure of the affinity of 3H-spiperone to its binding sites) was observed between the two groups. However, studies with unmedicated schizophrenic patients are needed to draw any definite conclusion. The role of serotonergic processes in the psychobiology of schizophrenia is discussed.
Department of Psychiatry, School of Medicine, Case Western Reserve University, Cleveland, OH.
R C
RC
Arora
H Y
HY
Meltzer
D000328:Adult; D014150:Antipsychotic Agents / Q000494:pharmacology; D005260:Female; D005625:Frontal Lobe / Q000378:metabolism*; D006801:Humans; D008024:Ligands; D008238:Lysergic Acid Diethylamide / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011985:Receptors, Serotonin / Q000378:metabolism*; D012559:Schizophrenia / Q000378:metabolism*; D013134:Spiperone / Q000378:metabolism; D014316:Tritium
D014150:Antipsychotic Agents; D008024:Ligands; D011985:Receptors, Serotonin; D014316:Tritium; D013134:Spiperone; D008238:Lysergic Acid Diethylamide